The ongoing problems at Sun Pharmaceutical, which resulted in the share price of the pharma major falling 37 per cent since September last year (see chart), might have prompted a rethink.
A source familiar with the developments said, “Valia is unlikely to proceed as a bidder in the bankruptcy proceedings of Jaypee.”
Valia is the brother-in-law of Sun Pharma founder Dilip Shanghvi. Valia and his family together own nearly a 3.5 per cent stake in Sun Pharma, according to the December 2018 public filings. Their stake is valued at Rs 3,300 crore.
According to a source close to the development, the resolution plans for Jaypee Infratech by all the bidders are expected by January 27 and the joint venture between Suraksha and Dosti Realty is unlikely to bid as both firms are facing headwinds in the real estate sector, apart from falling share prices of Sun Pharma.
“The debt investors of Suraksha Realty have recently asked the company to top up shares which are backing the bonds. This was due to the fall in share price of Sun Pharma as well as of SPARC (Sun Pharma Advanced Research). Lenders are expecting aggressive bids for Jaypee Infratech,” said another source close to the developments.
Jaypee Infratech, which has large tracts of land on both sides of the Yamuna Expressway, had defaulted on its debt of Rs 9,913 crore, forcing lenders to refer the company to the National Company Law Tribunal under the Insolvency and Bankruptcy Code (IBC) , 2016.
For the financial year 2016-17 (last available), Dosti Realty had a revenue of Rs 376 crore and a profit of Rs 40.35 crore, compared to a revenue of Rs 421 crore and a profit of Rs 76.3 crore reported in the previous financial year.
In May last year, lenders of Jaypee Infratech had rejected an offer made by Suraksha-Dosti combine, saying the upfront cash was too low and the offer of Rs 7,000 crore was not attractive enough. Later, in August 2018, the Supreme Court ordered a re-bid of Jaypee Infratech after an amendment in the IBC, which brought homebuyers on par with financial creditors
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)